Cerebras
CBRS
$211.30
-1.40%
Cerebras Systems Inc. is an AI company that designs and builds the world's largest semiconductor and AI infrastructure for training and inference, delivering its capabilities on-premise and via the cloud. As a niche player in the AI hardware market, it competes with established giants like Nvidia by offering a unique wafer-scale engine and software that integrates with popular ML frameworks. The company recently went public in May 2026, and its stock has been highly volatile, driven by massive revenue growth, a $25 billion backlog, and partnerships with OpenAI and AWS, but also by concerns over valuation, gross margin guidance, and the path to profitability. Investors are debating whether the stock is a buy on dips or a speculative trap, given its high valuation and the competitive pressures in the AI chip market.…
CBRS
Cerebras
$211.30
Related headlines
Investment Opinion: Should I buy CBRS Today?
Rating: Hold. The consensus is Strong Buy with an average target of $292, but the extreme valuation and post-IPO volatility warrant caution. The thesis is that Cerebras has exceptional growth potential but is priced for perfection, making it a speculative hold rather than a core position.
Sign up to view all
CBRS 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While Cerebras' growth metrics are stellar, the valuation and lack of profitability create a balanced risk/reward. The stock could rally if execution continues, but the technical downtrend and competitive pressures warrant caution. Upgrades to bullish would require evidence of sustained margin expansion and revenue acceleration, while downgrades to bearish would follow any signs of growth deceleration or margin erosion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cerebras's 12-month outlook, with a consensus price target around $292.00 and implied upside of +38.2% versus the current price.
Average Target
$292.00
0 analysts
Implied Upside
+38.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$209 - $340
Analyst target range
Cerebras is covered by 11 analysts, with a consensus recommendation of 'Strong Buy' and a mean recommendation score of 1.45 (where 1 is Strong Buy and 5 is Sell). The average target price is $292.00, which implies an upside of approximately 47% from the current price of $198.71. The target price range is $209.00 to $340.00, with the low target suggesting a modest 5% upside and the high target implying a 71% upside. The wide spread between the low and high targets indicates high uncertainty about the company's future performance. Recent ratings from firms like Rosenblatt, UBS, Wedbush, Morgan Stanley, and Needham have all been positive, with no downgrades, indicating that analysts remain bullish despite the stock's recent decline. The high target of $340 likely assumes that Cerebras will successfully execute on its backlog and achieve significant market share in the AI chip market, while the low target may reflect concerns about competition and margin pressure.
Drowning in data?
Find the real signal!
Bulls vs Bears: CBRS Investment Factors
Cerebras presents a classic high-risk, high-reward scenario. The bull case is anchored by explosive revenue growth (94% YoY), a massive $25B backlog, and improving margins, while the bear case rests on an extreme valuation (PS 131x) and ongoing losses. Currently, the bearish evidence is stronger given the stock's downtrend and valuation risk, but the company's growth trajectory and analyst support suggest significant upside if execution continues. The central tension is whether Cerebras can translate its backlog into profitable, sustainable growth before competitive pressures and valuation concerns overwhelm the story.
Bullish
- Hypergrowth with 94% YoY Revenue Surge: Q1 2026 revenue hit $193.4M, up 94.35% from $99.5M in Q1 2025, with accelerating sequential growth from $103.3M to $193.4M over four quarters. This demonstrates robust demand for AI infrastructure, backed by a $25B backlog and partnerships with OpenAI and AWS.
- Massive Backlog and Strategic Partnerships: The $25 billion backlog provides multi-year revenue visibility, while collaborations with OpenAI and AWS validate Cerebras' technology and market position. These relationships could drive sustained growth and potential expansion into new customer segments.
- Improving Profitability Trajectory: Net loss narrowed dramatically from -$105.7M in Q4 2024 to -$14.0M in Q1 2026, and gross margin expanded from 31.1% in Q2 2025 to 44.6% in Q1 2026. This trend suggests the company is moving toward breakeven, supported by positive EBITDA of $3.1M in Q1 2026.
- Strong Analyst Conviction: All 11 analysts rate CBRS a Strong Buy (mean score 1.45), with an average target of $292, implying 47% upside. Recent ratings from Rosenblatt, UBS, Wedbush, Morgan Stanley, and Needham are positive, with no downgrades, reflecting confidence in the company's growth story.
Bearish
- Extreme Valuation with PS Ratio of 131x: At $198.71, the price-to-sales ratio is 131.3x, far above the semiconductor industry average of ~10x. Even the forward PE of 206.7x implies the market is pricing in extraordinary earnings growth, leaving little room for error.
- Persistent Operating Losses: Operating margin was -7.8% in Q1 2026, and the company still posted a net loss of $14.0M. Heavy R&D spending ($75.5M in Q1) and sales investments continue to pressure profitability, with no clear timeline to sustained GAAP profits.
- Post-IPO Downtrend and High Volatility: The stock has fallen 36% from its first-day close of $311.07 to $198.71, with a max drawdown of -45.83%. Relative strength over the past month is -10.37% versus the S&P 500, indicating persistent selling pressure and weak momentum.
- Competitive Threat from Nvidia: Nvidia dominates the AI chip market with an established ecosystem and massive R&D budget. Cerebras' wafer-scale engine is niche, and any major technological leap by Nvidia could erode Cerebras' competitive advantage and market share.
CBRS Technical Analysis
Cerebras has been in a clear downtrend since its IPO, with the stock price falling from an opening of $311.07 on May 14, 2026, to a recent close of $198.71, a decline of approximately 36% from its first-day close. The stock is currently trading at $198.71, which is 51.4% of its 52-week range (low of $160.81, high of $386.34), indicating it is closer to the lows than the highs. This positioning suggests that the stock is in a bearish phase, with sellers in control, and the price action reflects a post-IPO correction as initial hype fades.
Beta
—
—
Max Drawdown
-45.8%
Largest decline past year
52-Week Range
$161-$386
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CBRS Return | S&P 500 |
|---|---|---|
| 1m | +19.6% | +2.8% |
| 3m | — | +4.2% |
| 6m | — | +11.3% |
| 1y | — | +21.5% |
| ytd | — | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRS Fundamental Analysis
Cerebras has demonstrated exceptional revenue growth, with Q1 2026 revenue of $193.4 million, a 94.35% year-over-year increase from $99.5 million in Q1 2025. The growth trajectory has been accelerating, with sequential revenue increases from $103.3 million in Q2 2025 to $135.7 million in Q3 2025, $171.4 million in Q4 2025, and $193.4 million in Q1 2026. This rapid expansion is driven by strong demand for its AI supercomputers, as evidenced by a $25 billion backlog and partnerships with major customers like OpenAI and AWS. However, the company is still unprofitable, with a net loss of $14.0 million in Q1 2026, though this loss has narrowed significantly from a loss of $105.7 million in Q4 2024. Gross margin improved to 44.6% in Q1 2026 from 31.1% in Q2 2025, but the company's operating margin remains negative at -7.8%, indicating that it is still investing heavily in R&D and sales.
Quarterly Revenue
$193406000.0B
2026-03
Revenue YoY Growth
+94.3%
YoY Comparison
Gross Margin
44.6%
Latest Quarter
Free Cash Flow
$145070500.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRS Overvalued?
Given that Cerebras has negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 131.3x, which is extremely high, reflecting the market's high expectations for future growth. The forward PE ratio is 206.7x, implying that analysts expect earnings to improve significantly, but the gap between the trailing PE (758.7x) and forward PE suggests that the market is pricing in substantial earnings growth. Compared to the semiconductor industry average PS ratio of around 10x, Cerebras trades at a massive premium, which is justified only if the company can maintain its hyper-growth and achieve profitability. Historically, the PS ratio has ranged from 101x to 925x over the past year, and the current 131x is near the lower end of that range, suggesting that the stock may be relatively cheaper than its own historical average, but still extremely expensive in absolute terms.
PE
758.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
848.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial. Cerebras has a negative debt-to-equity ratio of -0.45, indicating more liabilities than equity, though this is partly due to recent IPO proceeds. The company's operating margin is -7.8%, and it relies on external funding to support R&D and sales, with net losses of $14M in Q1 2026. While free cash flow is positive at $145M TTM, the high cash burn rate and dependence on continued growth to justify the valuation pose significant risks. If revenue growth decelerates or margins fail to expand, the stock could face severe repricing.
FAQ
The key risks are: 1) Financial: ongoing net losses of $14M in Q1 2026 and negative operating margin of -7.8%, which could persist and drain cash. 2) Competitive: Nvidia's dominance and potential technological advances could erode Cerebras' market share. 3) Valuation: the extreme PS ratio of 131x leaves little room for error, and any growth disappointment could trigger a sharp selloff. 4) Company-specific: customer concentration with OpenAI and AWS, and the recent gross margin guidance disappointment. The most severe risk is a combination of these factors leading to a 19% decline to the 52-week low.
Analysts have a Strong Buy consensus with an average target of $292, implying 47% upside. The bull case targets $340 (71% upside) with a 25% probability, the base case targets $209-$292 (5-47% upside) with a 50% probability, and the bear case targets $160.81-$209 (down to -19%) with a 25% probability. The most likely scenario is the base case, assuming continued strong growth but with some moderation and margin improvement.
CBRS is significantly overvalued relative to the semiconductor industry, with a PS ratio of 131x versus the industry average of ~10x. Even on a forward PE basis of 206.7x, the market is pricing in exceptional earnings growth. The stock is trading near the lower end of its historical PS range (101x-925x), suggesting it is cheaper than its own past, but still extremely expensive in absolute terms. This valuation implies the market expects Cerebras to become a dominant player in AI chips, with sustained hyper-growth and eventual profitability.
CBRS offers a compelling risk/reward for aggressive investors, with analysts seeing 47% upside to the average target of $292. However, the stock trades at 131x sales, leaving no margin of safety. It could be a good buy for those who believe in the AI infrastructure boom and can tolerate extreme volatility, but it is not suitable for conservative investors. The biggest downside risk is a growth slowdown or margin disappointment, which could send the stock toward the 52-week low of $160.81, a 19% drop from current levels.
CBRS is more suitable for long-term investors with a high risk tolerance, given its extreme volatility and speculative nature. The stock has a beta that is likely high, and its short-term price action has been highly volatile, with a 36% decline since IPO. For long-term investors, the potential for AI infrastructure growth could play out over 3-5 years, but the company needs to achieve profitability to justify its valuation. A minimum holding period of 3 years is recommended to ride out volatility and allow the growth story to unfold. Short-term trading is risky due to the lack of earnings visibility and the stock's sensitivity to news.